Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy By Ogkologos - June 16, 2025 673 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DeLLphi-304 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR EMA Recommends Extension of Indications for Olaparib September 24, 2020 Trastuzumab Deruxtecan Shows High Intracranial Response Rate in Patients with Active... August 9, 2022 Adding Capivasertib to Fulvestrant Results in Longer PFS in Patients with... June 5, 2023 Five-Year Follow-up of Adjuvant Dabrafenib plus Trametinib in Resected Stage III... September 11, 2020 Load more HOT NEWS Hairstylist Creates Custom Wigs & Donates Them To Cancer Patients Breast Cancer Survivors in Happy Romantic Relationships Are Healthier, Study Says A toolkit to address disparities in digitally enabled oncology trials After Chemotherapy, Selma Blair Embraces Her Buzzed “Patchy Charcoal” Hair
